All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085011" target="_blank" >RIV/00216224:14110/15:00085011 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.4149/BLL_2015_042" target="_blank" >http://dx.doi.org/10.4149/BLL_2015_042</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4149/BLL_2015_042" target="_blank" >10.4149/BLL_2015_042</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours

  • Original language description

    A retrospective analysis of consecutive patients (183 in total, of which 105 were males and 78 females) with gastrointestinal stromal tumour (GIST) was performed. The mean age was 61 years, median age 64 years. The most frequent localization of the tumour was stomach in 74 patients (40.4 %) and the small intestine in 46 patients (25.1 %). Two or more different synchronous or metachronous cancers occurred in 34 (18.6 %) patients with histologically confi rmed GIST. Ninety-six patients were treated with imatinib mesylate in palliative setting during the course of their disease. The therapy was fi nished in 60 patients and 36 patients have been treated so far. The median progression-free survival reached 32.9 months in the group of 96 patients treated with imatinib. The median overall survival in the group of 96 patients treated for metastatic disease reached 77 months. Two-year and 5-year survival was 85.2 % and 63.1 %, respectively.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Bratislava Medical Journal - Bratislavské lekárske listy

  • ISSN

    0006-9248

  • e-ISSN

  • Volume of the periodical

    116

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    SK - SLOVAKIA

  • Number of pages

    4

  • Pages from-to

    218-221

  • UT code for WoS article

    000351975100002

  • EID of the result in the Scopus database